Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Ularitide (Urodilatin)
Overview
Ularitide is a synthetic 32-amino acid peptide analogue of urodilatin, a natriuretic peptide produced in renal tubular cells. It binds to guanylyl cyclase A receptors to increase cyclic GMP, resulting in vasodilation, enhanced sodium excretion, and suppression of the renin-angiotensin-aldosterone system.
Mechanism of Action
The peptide was developed for treatment of acute decompensated heart failure with the goal of improving renal function and hemodynamics.
Research Summary & Key Findings
The TRUE-AHF trial (European Heart Journal, 2017) evaluated ularitide in over 2,000 patients with acute heart failure but did not meet its primary endpoint of cardiovascular mortality reduction. Despite promising earlier phase 2 data showing hemodynamic benefits, regulatory approval was not pursued following the neutral phase 3 results.
Clinical Status
Ularitide (Urodilatin) is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed: "Ularitide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Ularitide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Ularitide"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Cardiovascular
Eptifibatide (Integrilin)
FDA ApprovedA synthetic cyclic heptapeptide modeled after the KGD (Lys-Gly-Asp) disintegrin sequence found in the venom of the south...
View detailsNesiritide (Natrecor)
FDA ApprovedA recombinant form of human B-type natriuretic peptide (BNP), a 32-amino acid peptide naturally produced by ventricular ...
View detailsAngiotensin II (Giapreza)
FDA ApprovedA synthetic form of the endogenous octapeptide angiotensin II, the primary effector of the renin-angiotensin system. Ang...
View detailsSerelaxin (Relaxin-2)
InvestigationalSerelaxin is a recombinant form of human relaxin-2, a naturally occurring peptide hormone composed of two chains linked ...
View detailsNo lawful pathway today
Ularitide (Urodilatin) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.